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egy	 that	 leverages	 the	existing	capacities	of	 the	Global	 Influenza	Surveillance	and	





piratory	 infection	 (ARI)	 case	definitions	 for	hospital	 and	primary	care	 settings,	 re‐
spectively.	 Respiratory	 specimens	 were	 tested	 for	 RSV	 at	 the	 National	 Influenza	
Centre	(NIC)	using	standardized	molecular	diagnostics	that	had	been	validated	by	an	
2  |     BROOR et al
1  | INTRODUC TION
Respiratory	syncytial	virus	 (RSV)	 is	an	 important	cause	of	 respira‐
tory	infections,	with	the	most	severe	infections	occurring	in	young	
children,	 older	 adults,	 and	 adults	 with	 chronic	 co‐morbidities.1,2 
Acute	 lower	 respiratory	 infections	 (bronchiolitis	 and	 pneumonia)	
due	to	RSV	are	among	the	most	common	causes	of	hospital	admis‐
sion	(estimated	3.2	million	annually)	and	hospital	deaths	(estimated	





as	 recurrent	 wheeze	 and	 asthma	 later	 in	 childhood.6	 The	 burden	
of	severe	disease	and	deaths	from	RSV	 in	high‐risk	adults	remains	
uncertain	but	 initial	estimates	suggest	 that	 influenza	virus	 is	more	
common	than	RSV,	but	RSV	infection	has	a	higher	risk	of	death	than	
seasonal	 influenza	 in	 adults.7	 The	RSV	vaccine	development	 land‐
scape	is	evolving	rapidly.	There	are	currently	several	vaccine	candi‐
dates	and	monoclonal	antibodies	in	various	stages	of	clinical	trials.8,9 


















is	 likely	 to	be	 the	greatest,	have	 little	or	no	national	data	and	 low	
awareness	of	RSV	as	a	cause	of	disease.	Clinical	guidelines	for	the	
management	 of	 lower	 respiratory	 infections	 in	 children	 in	 LMICs	
such	 as	 the	 WHO	 Integrated	 Management	 of	 Childhood	 Illness	
(IMCI)	13	do	not	advocate	the	use	of	RSV	diagnostic	testing	as	yet	
and	 routine	 hospital	 information	 systems	 do	 not	 generally	 report	
data	on	RSV	which	can	 inform	national	 immunization	program	de‐
cision	making.	This	gap	 in	knowledge	may	 impede	evidence‐based	




more	 than	 two	million	 respiratory	 specimens	 annually	 to	monitor	
the	 spread	 and	 evolution	 of	 influenza	 viruses	 through	 a	 network	
of	about	150	well‐established	 laboratories	 in	114	countries	 repre‐
senting	91%	of	 the	world's	population.	The	GISRS	network	 is	 ide‐
ally	placed	as	a	platform	for	the	introduction	of	a	more	systematic	
testing	for	RSV	associated	with	respiratory	illness	as	it	already	uses	
molecular	 diagnostics	 on	 respiratory	 specimens	 and	 conditioned	
to	 report	 regular	 and	 disciplined	 reporting	 to	 a	 global	 platform.	
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2  | PILOTING THE STR ATEGY FOR RSV 
SURVEILL ANCE
The	 overall	 strategy	 aimed	 to	 leverage	 and	 build	 on	 the	 existing	














Three	 designated	 reference	 laboratories	 (Respiratory	 Viruses	
Branch,	Division	of	Viral	Diseases,	Centers	for	Disease	Control	and	
Prevention	 (CDC),	 United	 States;	 Public	 Health	 England,	 United	
Kingdom	 of	Great	 Britain	 and	Northern	 Ireland;	 and	 the	National	
Institute	 of	 Communicable	Diseases,	 South	 Africa)	 participated	 in	
the	 Quality	 Control	 for	 Molecular	 Diagnostics	 (QCMD)	 external	
quality	assurance	program	for	RSV.	The	National	Influenza	Centres	







respectively	 (Figure	 2).	 Respiratory	 specimens	were	 collected	 and	
transported	 according	 to	WHO	 guidelines	 16	 and	 batch‐tested	 at	
the	NIC	using	a	standardized	real‐time	RT‐PCR	assay	developed	by	
CDC	and	validated	against	commonly	used	RNA	extraction	systems	
and	 amplification	platforms.	 The	NICs	 had	 the	option	of	 using	 ei‐
ther	a	commercial	or	an	in‐house	developed	RT‐PCR	assay	provided	
it	 had	been	validated	against	 the	CDC	assay.	The	use	of	 enzymes	
and	reagents	for	the	RT‐PCR	assay	were	standardized	and	supplied	
by	the	International	Reagents	Resource,	CDC.	The	designated	RSV	
reference	 laboratories	 provided	 technical	 and	 training	 support	 to	
the	NICs	on	request.	The	WHO	FluMart	data	reporting	platform	for	
influenza	was	adapted	for	countries	to	directly	upload	anonymized	
case‐based	RSV	data	using	 their	 own	database	 structure	 and	 sys‐
tem	without	having	to	transform	it.	Interactive	data	visualization	of	
trends,	distributions,	and	other	outputs	were	developed	that	could	
be	 stratified	 by	 country,	 year,	 period,	 age,	 hospital	 or	 outpatient‐
based	 surveillance,	 and	presence	or	 absence	of	 fever.	An	external	
advisory	group	provided	oversight	to	the	pilot	project.
3  | OPPORTUNITIES AND CHALLENGES
The	RSV	 surveillance	 strategy	 aims	 to	 leverage	existing	national	 re‐
sources	 of	 the	 GISRS	 without	 adversely	 impacting	 its	 established	







































F I G U R E  1  Countries	participating	in	the	WHO	global	RSV	surveillance
F I G U R E  2  Algorithm	for	selection	of	
patients	for	testing	for	RSV
     |  5BROOR et al
3.1 | Opportunities presented by the pilot







that	national	 support	 to	GISRS	 is	maintained	and	 increased.	Thus,	
the	pilot	represents	an	opportunity	to	influence	emerging	ideas	on	
RSV	surveillance	and	establish	global	guidelines	and	best	practice.
Virologic	surveillance	 in	 the	 future	will	allow	for	monitoring	of	
any	genetic	drift	and	its	relationship	to	antigenic	change.	These	data	
could	be	used	 to	 identify	 escape	mutants	 and	assess	 the	possible	


















Respiratory	 syncytial	 virus	 surveillance	may	 not	 yield	 detailed	
and	robust	burden	of	disease	estimates	in	many	LMICs.	Nevertheless,	
national	policymakers	should	still	find	estimates	of	RSV‐associated	





















community‐based	 surveillance,	 respectively.	 In	 addition,	 the	 case	
definition	 for	 infants	aged	 less	 than	6	months	 included	apnea	and	
sepsis	 from	 undetermined	 cause	 (Table	 1).	 Second,	 the	 RSV	 dis‐
ease	burden	is	highest	 in	children	aged	 less	than	2	years,21	an	age	
group	historically	underrepresented	in	influenza	surveillance	by	the	










































6  |     BROOR et al
at	the	sentinel	site.	Ideally,	the	sampling	fraction	would	be	specified	
for	each	week,	age	group,	and	sentinel	surveillance	site.	For	surveil‐




Three	 major	 laboratory‐related	 concerns	 were	 considered.	 First,	
most	NICs	were	already	testing	for	RSV	and	other	respiratory	viruses	
using	 commercial	 or	 laboratory‐developed	 molecular	 diagnostics,	
either	 monoplex	 or	 multiplex	 RT‐PCR	 assays	 as	 well	 as	 antigen‐








using	 commercial	 or	 other	 laboratory‐developed	 RT‐PCR	 assays	





















made	 to	 tackle	 these	 in	 the	development	of	 the	RSV	surveillance	
pilot	 approach.	 The	 pilot	 collected	 data	 to	 monitor	 performance	
at	 each	 site	 and	will	 be	 able	 to	 report	 on	 the	 degree	 of	 success	
achieved	using	 the	 approach	 adopted.	 For	 example,	 the	pilot	will	
report	on	the	relative	performance	of	the	case	definitions	for	the	




surveillance.	 Although	 two	 studies	 from	 Nepal	 and	 South	 Africa	
have	 reported	 that	 RSV	 infection	 during	 pregnancy	 does	 not	 ad‐
versely	affect	the	pregnancy	outcomes	nor	that	post‐partum	RSV	














tion	 will	 also	 assist	 in	 assessment	 of	 the	 health	 costs	 associated	
with	 RSV.	 These	 data	will	 be	 important	 in	 health	 economical	 as‐
sessments	of	any	intervention	(such	as	vaccines).	Equally,	it	will	be	
important	to	raise	awareness	of	the	possibility	of	RSV	infection	in	
causing	 the	 respiratory	 disorders	 in	 older	 adults	 and	 those	 with	
chronic	medical	conditions.
Once	 RSV	 seasonality	 is	 better	 defined,	 it	may	 be	 possible	 to	
limit	site‐specific	surveillance	to	high	transmission	seasons	for	both	
RSV	and	influenza.	Once	RSV	case	definitions	have	been	evaluated,	
the	 need	 for	 ongoing	 individual	 case	 data	 will	 be	 reconsidered.	













GISRS	 has	 built	 close	 relationships	 with	Ministries	 of	 Health	 and	
policymakers	 in	 individual	countries.	This	 is	clearly	signaled	by	the	
financial	support	to	the	RSV	surveillance	pilot	provided	by	national	
GISRS	platforms.	The	pilot	served	to	strengthen	these	relationships	







appropriate	audiences	and	 respond	 to	 local	 comments	 and	needs.	
     |  7BROOR et al
Another	 possible	 approach	 to	 long‐term	 sustainability	 may	 be	 to	
integrate	 this	 surveillance	within	a	broader	 (respiratory)	 infectious	
disease	 surveillance	platform	 in	 secondary	 care	 that	 encompasses	





The	pilot	 project	 should	help	define	 the	minimum	dataset	 and	
minimum	surveillance	effort	 required	 to	maintain	a	 functional	and	
useful	RSV	surveillance,	in	a	cost‐efficient	manner	and	without	ad‐
versely	 impacting	 on	 essential	 influenza	 surveillance.	 Information	
obtained	should	also	help	 in	better	understanding	 the	 relative	 im‐
portance	 of	 RSV	 as	 a	 cause	 of	 healthcare	 burden	 in	 various	 risk	
groups	and	 the	overlap	between	 influenza	and	RSV	viral	 infection	


















in	 the	 informal	 consultations	 in	March	 2015,	 February	 2016,	 and	
June	2016	 that	 led	 to	 the	development	of	 the	WHO	RSV	surveil‐
lance	strategy.	We	are	grateful	to	the	National	Influenza	Centres	and	
the	Ministries	of	Health	of	 the	participating	countries,	 for	piloting	
the	 RSV	 surveillance	 strategy.	We	 thank	 the	 Respiratory	 Viruses	
Branch,	Division	of	Viral	Diseases,	CDC,	Atlanta;	the	Public	Health	
England	 at	Colindale;	 and	 the	National	 Institute	of	Communicable	
Diseases	at	 Johannesburg	 for	providing	 support	 as	RSV	 reference	
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